148 related articles for article (PubMed ID: 20701957)
1. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
2. [Influence of estrogen and progestin on nm23-H1 expression in epithelial ovarian cancer cell lines via activation of phosphorylation signaling].
Hua KQ; Yao LQ; Cao Q; Huang Y; Zhao YQ; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):756-61. PubMed ID: 17327034
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
6. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 expression in primary and recurrent ovarian carcinomas.
Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
9. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling.
Sung YK; Hwang SY; Farooq M; Kim JC; Kim MK
Exp Mol Med; 2003 Aug; 35(4):257-62. PubMed ID: 14508064
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
11. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells.
De Santis G; Miotti S; Mazzi M; Canevari S; Tomassetti A
Oncogene; 2009 Mar; 28(9):1206-17. PubMed ID: 19151754
[TBL] [Abstract][Full Text] [Related]
13. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.
Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T
Oncology; 2009; 77(1):22-32. PubMed ID: 19440000
[TBL] [Abstract][Full Text] [Related]
14. Frequent silencing of the GPC3 gene in ovarian cancer cell lines.
Lin H; Huber R; Schlessinger D; Morin PJ
Cancer Res; 1999 Feb; 59(4):807-10. PubMed ID: 10029067
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G; Sailaja D
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model.
Peters MG; Farías E; Colombo L; Filmus J; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 2003 Jul; 80(2):221-32. PubMed ID: 12908826
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
[TBL] [Abstract][Full Text] [Related]
18. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
Capurro MI; Xiang YY; Lobe C; Filmus J
Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]